Fig 1: Protein expression of DCK in primary MCL samples, and their ex vivo sensitivity to nucleoside analogs. (A-B) Relative expression of deoxycytine kinase (DCK) in post-treatment primary MCL samples (R2, R6, R9, R10) compared to pre-treatment samples (D2, D6, D9, D10). (C) CD19-sorted PBMC cells were isolated from two leukemized araC-refractory MCL patients before (D9, D10) and 14 days after (R9, R10) administration of high-dose araC. The cells were ex vivo/in vitro exposed to araC (25 μM), fludarabine (Flu, 100 μM) and gemcitabine (Gem, 25 μM). Apoptosis was measured after 24 hours using standard Annexin-V-PE and flow cytometry. Apoptotic cells are shown as Annexin-V-PE-positive cells (Y axis). Basal apoptosis of drug-unexposed cells was subtracted from the apoptosis of the drug-exposed cells.